- Report
- March 2024
- 221 Pages
Global
From €2202EUR$2,450USD£1,931GBP
- Report
- February 2025
- 120 Pages
Denmark, Finland, ... Denmark, Finland, Iceland, Norway, Sweden
From €5348EUR$5,950USD£4,690GBP
- Report
- May 2024
- 90 Pages
United States
From €3550EUR$3,950USD£3,114GBP
- Report
- August 2022
- 120 Pages
Global
From €4045EUR$4,500USD£3,547GBP
- Report
- May 2024
- 277 Pages
Global
From €4494EUR$5,000USD£3,941GBP
- Report
- April 2024
- 279 Pages
Global
From €4494EUR$5,000USD£3,941GBP
- Report
- April 2025
- 85 Pages
India
From €3146EUR$3,500USD£2,759GBP
- Report
- February 2025
- 85 Pages
India
From €3146EUR$3,500USD£2,759GBP
- Report
- July 2024
- 185 Pages
Global
From €4045EUR$4,500USD£3,547GBP
- Report
- May 2024
- 185 Pages
Global
From €4045EUR$4,500USD£3,547GBP
- Report
- April 2024
- 187 Pages
Global
From €4045EUR$4,500USD£3,547GBP
- Report
- October 2023
- 126 Pages
North America
From €3595EUR$4,000USD£3,153GBP
- Report
- January 2022
- 90 Pages
Global
From €1438EUR$1,600USD£1,261GBP
€1798EUR$2,000USD£1,577GBP
- Report
- January 2022
- 125 Pages
Global
From €1798EUR$2,000USD£1,577GBP
€2247EUR$2,500USD£1,971GBP
- Report
- January 2022
- 90 Pages
Global
From €1438EUR$1,600USD£1,261GBP
€1798EUR$2,000USD£1,577GBP
- Report
- January 2022
- 150 Pages
Global
From €1079EUR$1,200USD£946GBP
€1348EUR$1,500USD£1,182GBP
- Report
- January 2022
- 70 Pages
Global
From €719EUR$800USD£631GBP
€899EUR$1,000USD£788GBP
- Report
- March 2024
- 200 Pages
Global
From €3730EUR$4,150USD£3,271GBP
- Report
- March 2024
- 200 Pages
Global
From €3730EUR$4,150USD£3,271GBP
- Report
- August 2023
- 145 Pages
Global
From €2831EUR$3,150USD£2,483GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more